JZP458 -Asparaginase Erwinia Chrysanthemi (Recombinant) for the Treatment of Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LBL) in Adult and Pediatric Patients Who Have Developed Hypersensitivity or Silent Inactivation to E. Coli-derived Asparaginase
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Crisantaspase (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 20 Jul 2021 Status changed from recruiting to completed.
- 12 May 2021 New trial record
- 10 May 2021 According to a Bionical Emas media release, the CRO announced the launch of this expanded access program in the U.S.